267 related articles for article (PubMed ID: 37821934)
21. Single-Agent Neoadjuvant Immunotherapy With a PD-1 Antibody in Locally Advanced Mismatch Repair-Deficient or Microsatellite Instability-High Colorectal Cancer.
Pei F; Wu J; Zhao Y; He W; Yao Q; Huang M; Huang J
Clin Colorectal Cancer; 2023 Mar; 22(1):85-91. PubMed ID: 36528470
[TBL] [Abstract][Full Text] [Related]
22. Economic evaluation of sintilimab plus chemotherapy vs. pembrolizumab plus chemotherapy for the treatment of first-line advanced or metastatic squamous NSCLC.
Chen P; Wang X; Zhu S; Li H; Rui M; Wang Y; Sun H; Ma A
Front Public Health; 2022; 10():956792. PubMed ID: 36016894
[TBL] [Abstract][Full Text] [Related]
23. Cost effectiveness of pembrolizumab vs chemotherapy as first-line treatment for metastatic NSCLC that expresses high levels of PD-L1 in Switzerland.
Bhadhuri A; Insinga R; Guggisberg P; Panje C; Schwenkglenks M
Swiss Med Wkly; 2019 Dec; 149():w20170. PubMed ID: 31880807
[TBL] [Abstract][Full Text] [Related]
24. KEYSTEP-008: phase II trial of pembrolizumab-based combination in MSI-H/dMMR metastatic colorectal cancer.
André T; Pietrantonio F; Avallone A; Gumus M; Wyrwicz L; Kim JG; Yalcin S; Kwiatkowski M; Lonardi S; Zolnierek J; Odeleye-Ajakaye A; Leconte P; Fogelman D; Kim TW
Future Oncol; 2023 Dec; 19(37):2445-2452. PubMed ID: 37701986
[TBL] [Abstract][Full Text] [Related]
25. Association Between Survival and Metastatic Site in Mismatch Repair-Deficient Metastatic Colorectal Cancer Treated With First-line Pembrolizumab.
Saberzadeh-Ardestani B; Jones JC; Hubbard JM; McWilliams RR; Halfdanarson TR; Shi Q; Sonbol MB; Ticku J; Jin Z; Sinicrope FA
JAMA Netw Open; 2023 Feb; 6(2):e230400. PubMed ID: 36811859
[TBL] [Abstract][Full Text] [Related]
26. Comparative Effectiveness of Immune Checkpoint Inhibitors vs Chemotherapy in Patients With Metastatic Colorectal Cancer With Measures of Microsatellite Instability, Mismatch Repair, or Tumor Mutational Burden.
Quintanilha JCF; Graf RP; Fisher VA; Oxnard GR; Ellis H; Panarelli N; Lin DI; Li G; Huang RSP; Ross JS; Myer PA; Klempner SJ
JAMA Netw Open; 2023 Jan; 6(1):e2252244. PubMed ID: 36689222
[TBL] [Abstract][Full Text] [Related]
27. Cost-effectiveness analysis of pembrolizumab for treatment of US patients with persistent, recurrent, or metastatic cervical cancer.
Shi Y; Chen J; Shi B; Liu A
Gynecol Oncol; 2022 Feb; 164(2):379-385. PubMed ID: 34920886
[TBL] [Abstract][Full Text] [Related]
28. The cost effectiveness of pembrolizumab versus chemotherapy or atezolizumab as second-line therapy for advanced urothelial carcinoma in the United States.
Slater RL; Lai Y; Zhong Y; Li H; Meng Y; Moreno BH; Godwin JL; Frenkl T; Sonpavde GP; Mamtani R
J Med Econ; 2020 Sep; 23(9):967-977. PubMed ID: 32412387
[No Abstract] [Full Text] [Related]
29. Cost-effectiveness analysis of pembrolizumab plus chemotherapy for patients with recurrent or metastatic cervical cancer in China.
Zheng Z; Song X; Qiu G; Xu S; Cai H
Curr Med Res Opin; 2023 Mar; 39(3):433-440. PubMed ID: 36757780
[TBL] [Abstract][Full Text] [Related]
30. Cost-effectiveness analysis of pembrolizumab versus chemotherapy as first-line treatment in locally advanced or metastatic non-small cell lung cancer with PD-L1 tumor proportion score 1% or greater.
She L; Hu H; Liao M; Xia X; Shi Y; Yao L; Ding D; Zhu Y; Zeng S; Shen L; Huang J; Carbone DP
Lung Cancer; 2019 Dec; 138():88-94. PubMed ID: 31655368
[TBL] [Abstract][Full Text] [Related]
31. Cost-effectiveness of Pembrolizumab in Second-line Advanced Bladder Cancer.
Sarfaty M; Hall PS; Chan KKW; Virik K; Leshno M; Gordon N; Moore A; Neiman V; Rosenbaum E; Goldstein DA
Eur Urol; 2018 Jul; 74(1):57-62. PubMed ID: 29576265
[TBL] [Abstract][Full Text] [Related]
32. Pembrolizumab vs the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Cost-Effectiveness Analysis.
Lang Y; Dong D; Wu B
Clin Drug Investig; 2020 Dec; 40(12):1137-1146. PubMed ID: 33095408
[TBL] [Abstract][Full Text] [Related]
33. Cost-effectiveness analysis of pembrolizumab monotherapy and chemotherapy in the non-small-cell lung cancer with different PD-L1 tumor proportion scores.
Zhou K; Jiang C; Li Q
Lung Cancer; 2019 Oct; 136():98-101. PubMed ID: 31476529
[TBL] [Abstract][Full Text] [Related]
34. Real-World Treatment Patterns and Clinical Outcomes for Standard of Care Regimens in Patients with Deficient MMR or MSI-High Metastatic Colorectal and Non-Colorectal Cancer: A Retrospective Chart Review Study in France.
Roset M; Amonkar M; Patel R; Lara N; Kothari S
Adv Ther; 2022 Mar; 39(3):1215-1229. PubMed ID: 35025060
[TBL] [Abstract][Full Text] [Related]
35. Pembrolizumab in advanced recurrent endometrial cancer: A cost-effectiveness analysis.
Barrington DA; Dilley SE; Smith HJ; Straughn JM
Gynecol Oncol; 2019 May; 153(2):381-384. PubMed ID: 30808517
[TBL] [Abstract][Full Text] [Related]
36. A Phase II Study of Avelumab Monotherapy in Patients with Mismatch Repair-Deficient/Microsatellite Instability-High or POLE-Mutated Metastatic or Unresectable Colorectal Cancer.
Kim JH; Kim SY; Baek JY; Cha YJ; Ahn JB; Kim HS; Lee KW; Kim JW; Kim TY; Chang WJ; Park JO; Kim J; Kim JE; Hong YS; Kim YH; Kim TW
Cancer Res Treat; 2020 Oct; 52(4):1135-1144. PubMed ID: 32340084
[TBL] [Abstract][Full Text] [Related]
37. Pembrolizumab and lenvatinib versus carboplatin and paclitaxel as first-line therapy for advanced or recurrent endometrial cancer: A Markov analysis.
Ackroyd SA; Huang ES; Kurnit KC; Lee NK
Gynecol Oncol; 2021 Aug; 162(2):249-255. PubMed ID: 34103196
[TBL] [Abstract][Full Text] [Related]
38. Cost-Effectiveness of Cemiplimab Versus Standard of Care in the United States for First-Line Treatment of Advanced Non-small Cell Lung Cancer With Programmed Death-Ligand 1 Expression ≥50.
Kuznik A; Smare C; Chen CI; Venkatachalam M; Keeping S; Atsou K; Xu Y; Wilson F; Guyot P; Chan K; Glowienka E; Konidaris G
Value Health; 2022 Feb; 25(2):203-214. PubMed ID: 35094793
[TBL] [Abstract][Full Text] [Related]
39. Cost Effectiveness of Adding Pembrolizumab to Platinum and Fluoropyrimidine-Based Chemotherapy as First-Line Treatment for Advanced Esophageal Cancer: A US Healthcare Payer's Perspective.
Qu T; Zhang S; Zhong Y; Meng Y; Guo H; Joo S; Enzinger PC
Pharmacoeconomics; 2022 Dec; 40(12):1247-1259. PubMed ID: 36241842
[TBL] [Abstract][Full Text] [Related]
40. Immune Checkpoint Blockade Therapy in Patients With Colorectal Cancer Harboring Microsatellite Instability/Mismatch Repair Deficiency in 2022.
André T; Cohen R; Salem ME
Am Soc Clin Oncol Educ Book; 2022 Apr; 42():1-9. PubMed ID: 35471834
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]